Compliance rates
LUNG CANCER
The HRQoL analysis population included 789 patients: 533 in the tislelizumab arm and 256 in the docetaxel arm. At baseline, 530 (99.4%) of the 533 patients in the tislelizumab arm and 254 (99.2%) of the 256 patients in the docetaxel arm were compliant with the QLQ‐C30; at week 12, 368 (96.6%) of 381 and 109 (90.1%) of 121 patients, respectively, were compliant; at week 18, 318 (98.8%) of 322 and all 78 (100%) patients, respectively, were compliant (Table Compliance Rates for HRQoL Assessments.Abbreviations: HRQoL, health‐related quality of life; QLQ‐C30, Quality of Life Questionnaire Core 30 items; QLQ‐LC13, Quality of Life Questionnaire Lung Cancer 13 items.